Mark E. Dmytruk - Apr 6, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Chief Financial Officer
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Apr 6, 2023
Transactions value $: -$986
Form type: 4
Date filed: 4/11/2023, 05:03 PM
Previous filing: Apr 5, 2023
Next filing: May 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Options Exercise		+1.64K	+0.28%		577K	Apr 6, 2023	Direct	F1, F2
transaction	DNA	Class A Common Stock	Sale	-$986	-740	-0.13%	$1.33	576K	Apr 10, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Class B Common Stock	Options Exercise		-1.64K	-0.25%		648K	Apr 6, 2023	Class A Common Stock	1.64K		Direct	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F2	Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F3	Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F4	Includes shares of Class B Common Stock that are subject to vesting conditions.

Remarks:

Chief Financial Officer